Shionogi Xocova CHMP: First Oral COVID PEP Pill

The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on July 23, 2026 recommending marketing authorization for Zokovea (ensitrelvir), Shionogi’s oral antiviral, for post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents 12 years and older following contact with an infected individual. Zokovea will be the first oral antiviral approved in the EU for COVID-19 prevention after exposure.

The EU regulatory step

A CHMP positive opinion is the final scientific step before European Commission approval, which typically follows within 67 days. The EU decision is a regulatory catch-up: the FDA approved Xocova (the US brand name for ensitrelvir) on June 1, 2026, ahead of its June 16 PDUFA date, making it the first and only oral antiviral approved for COVID-19 PEP in the US. Japan approved it in March 2026.

Shionogi trades as an OTC ADR in the US under ticker SGIOY, closing at $8.68 on July 23 with modest volume of roughly 182,000 shares. The thin US float makes this more of a pharma innovation story than a tradable biotech catalyst for most US investors. Shionogi is listed primarily on the Tokyo Stock Exchange.

The clinical evidence

The approval rests on SCORPIO-PEP, the only Phase 3 study of an oral antiviral to meet the primary endpoint of preventing symptomatic COVID-19 following exposure. The trial enrolled 2,041 participants in the primary analysis population regardless of vaccination status. Ensitrelvir reduced the risk of symptomatic COVID-19 by 67% versus placebo through Day 10: 2.9% of ensitrelvir recipients developed symptomatic COVID-19 versus 9.0% on placebo (risk ratio 0.33; 95% CI 0.22 to 0.49; p<0.0001). Results were published in the New England Journal of Medicine on May 14, 2026.

In a prespecified subgroup of participants with at least one risk factor for severe disease, the relative risk reduction reached 76%: 2.4% on ensitrelvir versus 9.9% on placebo (risk ratio 0.24; 95% CI 0.12 to 0.49). The drug was generally well tolerated, with adverse event rates of 15.1% on ensitrelvir versus 15.5% on placebo, and no reports of altered taste (dysgeusia), a side effect that complicates Paxlovid use.

Why a preventive pill matters

Ensitrelvir is a 3CL protease inhibitor that blocks viral replication. Unlike Paxlovid (nirmatrelvir/ritonavir), which is approved only to treat active infection, Xocova is taken after exposure but before symptoms develop, blocking the virus during the critical window between contact and symptom onset. The five-day regimen is three tablets on Day 1, then one tablet daily through Day 5, and it lacks the ritonavir drug-interaction burden that limits Paxlovid use in patients on common medications.

The PEP strategy fills a gap: no oral antiviral has been approved to prevent COVID-19 after exposure, and household and institutional outbreaks continue to occur. The preventive antiviral category is still young; Gilead’s lenacapavir for HIV PrEP is the closest analogue, a long-acting preventive in a different viral indication. The 67% risk reduction is a strong efficacy signal for a preventive oral drug, and the higher-risk subgroup data suggests particular benefit in the patients most likely to need protection.

What to watch next

Commercial uptake in the US, where Xocova has been on the market for roughly two months. The key question is whether prescribers adopt a preventive pill for a disease most people now treat as routine, and whether payers reimburse it. Watch for early prescription data in Shionogi’s Q2 fiscal 2026 earnings.

Source: Shionogi press release | EMA CHMP meeting highlights, July 2026